Peter Seufer-Wasserthal

Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany.

Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA.

Origenis GmbH is a German biopharmaceutical company that specializes in developing small molecule medicines and diagnostics for neurodegenerative and neuroinflammatory diseases. The private company is based in Martinsried, Germany. The company's unique capabilities in drug design, compound synthesis, and characterization allow them to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Origenis has a significant IP and R&D portfolio that ensures strong patent protection. Origenis was founded in 2005, and the CEO is Michael Almstetter.

Sestina Bio LLC operates a platform for automated synthetic biology. It provides technology centric, R&D platform to provide cutting edge solutions to sustainably feed and clothe. The firms approach is to integrate tools for genome editing, single cell biology, and machine learning to transform ability to engineer and harness biological function. The company was founded by William Wayne Colston, Jr. and is headquartered in Pleasanton, CA.